Madagascar’s invoice
The island nation of Madagascar recently shared its touted remedy for Covid-19, named Covid-Organics, with Nigeria. But if you thought it was a gesture of African brotherly benefaction, perish the thought. There is an asking price of €170,000 (N78, 200,000) attached.
Nigeria’s allocation of the drug was brought in tow penultimate weekend by Guinea Bissau President Umaro Sissoco Embalo, who came calling on President Muhammadu Buhari in Abuja. Although the exact quantity of the consignment is not known, it apparently wasn’t beyond the oversight of his visiting excellency. Good enough, Nigeria did not rush into dispensing the drug. President Buhari made clear the Madagascar remedy wasn’t like a magic wand Nigeria was waiting for in its battle against coronavirus. He said the solution would be run through local verification and validation processes before being dispensed to Covid-19 patients.
Now we know ‘there is no free lunch even in Freetown,’ as they say. A source told The Nation last weekend: “For our consignments in Guinea Bissau, Madagascar has asked Nigeria to pay over €170,000 (N78, 200,000). We have received the invoice because the African country has made us to realise that the drugs are not being given out free. We are being asked to pay for the drugs yet to be validated. Since the AU (African Union) directed the supply of the drugs to African countries, we may have no choice than to pay for it.”
Well, aggressive marketing has no doubt helped the visibility of Covid-Organics, but that isn’t sufficient for the drug to exact such princely costs. This is more so as Madagascar last weekend reported Covid-19-related death of a 57-year-old medical worker – suggesting the herbal tonic isn’t after all impregnable. Besides, whereas the country disclosed the extract’s source as being Artemisia, a bitterroot used in malaria drugs, it patented it in exclusivity by withholding info on other ingredients.
The asking price can considerably help the work of Nigerian inventors rather than be thrown on a product patented in exclusivity by its foreign inventor. By all means, we have a choice: we can return the product to sender and rather concentrate on funding the work of local researchers. (The Nation)